Biofrontera and Allergan sign marketing and distribution agreement for Ameluz® in Spain - Seite 2

weeks after the last PDT in 85% and 87% of patients(1). The treatment can be
repeated after three months if residual lesions remain. In a direct head to head
comparison against a cream containing 16% methyl-aminolevulinate (MAL), 85% of
the patients were totally cleared from all lesions with Ameluz® while the MAL
cream cleared only 68% of the patients when LED light sources were used(1). As
with any PDT, the most common side effects occurred at the site of application
and included irritation, erythema, pain, pruritis and odema(1).

Other treatment options have lower clinical efficacy, longer-lasting side
effects and many result in visible scars or pigmentation changes(2). Actinic
keratosis is mostly seen in fair-skinned people on skin areas that have had
long-term sun exposure(3). The condition affects about 10% of the entire
Caucasian population world-wide(4). About 5-20% of patients with actinic
keratosis lesions develop malignant and potentially fatal squamous cell
carcinomas(5).

About Biofrontera
Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The
Biofrontera group aims at attending and treating the skin, recognizing the
aesthetic needs of a person´s visual reflection. Biofrontera is listed at the
regulated market of the Düsseldorf stock exchange under the symbol B8F and the
ISIN number DE0006046113.
www.biofrontera.com

This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forward-
looking statements to reflect future events or developments.

References

1.) Ameluz® Summary of Product Characteristics; www.ema.europa.eu
2.) Lawrence, N., Cox, S. E., Cockerell, C. J., Freeman, R. G., & Cruz, P. D.
Jr., 1995, Arch.Dermatol, 131, 176-181.
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J.,
Lee, J. H., & Fox, T. L., 2004, J Am.Acad.Dermatol, 50, 714-721.
Stockfleth, E. & Kerl, H., 2006, Eur. J. Dermatol. 16, 599-606.
3.) Salasche SJ., 2000, Am Acad Dermatol, 42, 4-7.
4.) Frost, C. A. & Green, A. C., 1994, Br J Dermatol, 131, 455-464.
Memon, A. A., Tomenson, J. A., Bothwell, J., & Friedmann, P. S., 2000, Br J
Dermatol, 142, 1154-1159.
5.) Braathan LR, Szeimes RM, Basset-Seguin N et al., 2007 J Am Acad Dermatol,
56, 125-143.

For further information please contact:
Anke zur Mühlen
Director PR/IR
+ 49 214 87632 0
+ 49 214 87632 90
[e-mail]
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

--- End of Message ---

Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany

WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Börse Düsseldorf;

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1598259]

Wertpapiere des Artikels:
DE0006046113